Q-omics provides the consensus-scored SPEF1 profile across patient tissues and cancer cell-line models. SPEF1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SPEF1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, SPEF1 RNA expression shows 14,974 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KICH, and TGCT as cancer lineages where SPEF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPEF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPEF1 survival associations across molecular data types. SPEF1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPEF1 RNA expression–survival associations across cancer types. High SPEF1 expression shows unfavorable associations in LIHC and LGG, but favorable associations in UVM, ACC, KIRP and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SPEF1 RNA expression.
This table summarizes SPEF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SPEF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPEF1 shows lower tumor expression in KICH, THCA, LUAD and LUSC and higher tumor expression in KIRP and COAD. The KICH box plot shows higher SPEF1 RNA expression in normal versus tumor tissue (log2 FC = −2.235, t-test p < 0.001).
This table shows molecular features associated with SPEF1 in patient tissues and cancer cell lines. In patient samples, SPEF1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SPEF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
